Terms Accepted

Samsung · captured 2026-09-06T20:26:38Z samsung·PIT·4169ed CAP-03582

Samsung Ads Pharma Case Study 25 [PDF]

The text as it stood on 2026-09-06. This document was captured 6 times that day, so the date on its own does not name one of them — it returns the last. To cite exactly this capture, use /d/samsung-ads-pharma-case-study-25-pdf/v/cap-03582, which will always mean this one and nothing else.

Captured
2026-09-06
Words
273
HTTP
200
Size
504.9 KB
State
First capture

PDF (published) Extracted text

Cite this capture

Everything a footnote needs, including the checksum, so a reader can confirm they are looking at the same bytes you did. Select and copy. 

Samsung, “Samsung Ads Pharma Case Study 25 [PDF]”.
Captured 2026-09-06T20:26:38Z by Terms Accepted.
Permalink: https://termsaccepted.org/d/samsung-ads-pharma-case-study-25-pdf/v/cap-03582
Original:  https://go.samsungads.com/l/880362/2026-03-26/81trk/880362/1774536780TZPwtFGC/Samsung_Ads_Pharma_Case_Study_25.pdf
SHA-256:   c67f729f5802abbf87920f4e7db3d665d7293cc826041f08999c8f9706460e16
Provenance: captured directly from the publisher.
Verify this file — SHA-256

The file below is stored under this checksum, so altering it would change its name. Download the copy above and run sha256sum on it: if the value differs from this one, you are not looking at what we captured.

c67f729f5802abbf87920f4e7db3d665d7293cc826041f08999c8f9706460e16

Also captured that day

5

Every reading of this document on 2026-09-06. They may be identical; where they are not, the difference is a change the publisher made within a single day.

CapturedPermalinkWordsState
2026-09-06T06:23:43Z cap-02285 0 First capture
2026-09-06T15:07:44Z cap-02630 0 First capture
2026-09-06T17:19:50Z cap-02955 0 First capture
2026-09-06T18:47:04Z cap-03280 0 First capture
2026-09-06T20:10:36Z cap-03545 0 First capture

The document

Get in touch at adsales@samsung.comsamsungads.com Source: Samsung Ads proprietary ACR data; IQVIA 2022 Campaign Report. Dynamic strategies unlock success across multiple lines of business Background A leading pharmaceutical company aimed to extend the proven success of their RX initiatives to their various OTC lines of business. Recognizing that OTC brands cater to a broader target audience, the company turned to Samsung to develop a new strategy to not only reach this more general market, but also achieve incremental reach against their traditional linear efforts. Driving results for a leading pharma brand RXStrategy Leverage Samsung’s scale paired with healthcare data segments and measurement solutions to reach hyper-targeted, diagnosed audiences Results Audience Quality CTV + diagnosed audiences proved to be highly efficient in achieving diagnosed audience quality and reaching diagnosed unique viewers. OTCStrategy Leverage CTV to reach a less-targeted audience at a lower cost, while achieving incremental reach against existing linear buys Results Outcomes Across multiple OTC brands, Samsung Ads drove significant incremental reach against linear campaigns: Efficiency Samsung remained the most efficient partner on the plan following the 2022 CTV campaign launch Efficiency The majority of impressions fell within the brand’s target audience without the need to pay for additional demo targeting 5.5%AQ score, above IQVIA’s 4.8 benchmark* for this particular diagnosed audience 7.3Kincremental new patient office visits Dental care brand 1: 32% incremental lift; 63% within A25-54 demo target vs. linear’s 41% Dental care brand 2: 43% incremental lift; 72% within A25-54 demo target vs. linear’s 41% Vaccine brand: 15% incremental lift; 70% within A50+ demo target vs. linear’s 78% Injectable antiretroviralbrand: 11% incremental lift; 53% within A25-54 demo target vs. linear’s 52%